Latest stories on MBRX
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
Stocktwits News34 · bearishearnings
Moleculin Biotech Updates Investors With New Presentation
TipRanks55 · neutralgeneral
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
TipRanks63 · neutralproduct/pr
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
TipRanks63 · neutralproduct/pr
Moleculin Biotech Releases Updated Investor Information Presentation
TipRanks55 · neutralgeneral
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
TipRanks63 · neutralproduct/pr
Moleculin Biotech GAAP EPS of -$3.54 misses by $2.08
Seeking Alpha34 · bearishearnings